Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Condition Directory

Leukemia clinical trials

Directory of U.S. ClinicalTrials.gov public records for Leukemia. Browse Leukemia recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By Clinical Trials Finder Guidance last reviewed June 10, 2026 Data synced November 1, 2026 Report an issue

ClinicalTrials.gov public records Last synced Oct 31, 2026, 9:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
5290
Shown on this page
12
Current sort
Recently updated
Condition scope
Leukemia
Additional filters apply within this condition.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

How Leukemia studies are organized in the registry

“Leukemia” is an umbrella term; in practice most records name the specific subtype, and this directory has dedicated pages for the major ones — acute myeloid (AML), chronic lymphocytic (CLL), and acute lymphoblastic (ALL) leukemia. Use this page when scanning across subtypes, and the subtype pages when you know which disease you mean.

Terms that often appear in related listings
AML CLL ALL CML relapsed refractory

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Filter and sort this condition

These controls apply only within Leukemia. Default order is Recently updated. Add location, sponsor, treatment, or recruitment status to narrow this condition page further.

Reset condition filters
Clear filters
Showing 1105–1116 of 5,290 matching trials for Leukemia.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Open in full search
Available No phase listed Expanded access

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

NCT05776134
View directory record Official record
Conditions
Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia
Interventions
Brexucabtagene Autoleucel
Biological
Lead sponsor
Kite, A Gilead Company
Industry
Eligibility
18 Years and older
U.S. locations
44
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 31, 2026, 9:56 PM EDT
Recruiting No phase listed Observational

Backtracking Leukemia-Typical Somatic Mutations in Cord Blood

NCT05014165
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Interventions
Cord blood Sample Collection, Case identification and recruitment, Questionnaire Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 25 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 31, 2026, 9:56 PM EDT
Completed Phase 3 Interventional Results available

A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

NCT04102020
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML)
Interventions
Venetoclax, Azacitidine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
27
States / cities
Mobile, Alabama • Fountain Valley, California • Los Angeles, California + 21 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 31, 2026, 9:56 PM EDT
Active, not recruiting Phase 2 Interventional

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT04329325
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive
Interventions
Blinatumomab, dasatinib, dexamethasone, methotrexate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 31, 2026, 9:56 PM EDT
Active, not recruiting Phase 1 Interventional

A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies

NCT03085173
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia (CLL), Relapsed, Refractory
Interventions
EGFRt/19-28z/4-1BBL CAR T cells
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 31, 2026, 9:56 PM EDT
Completed Not applicable Interventional

Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study

NCT05972577
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Plasma Cell Myeloma
Interventions
Health Promotion and Education, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
60 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 31, 2026, 9:56 PM EDT
Recruiting Not applicable Interventional

Standard-of-Care Reduced-Intensity Conditioning (RIC) With 200 Versus 400 cGy of Total Body Irradiation (TBI) in Patients With Acute Leukemia Undergoing First Allogeneic Blood or Marrow Transplantation (BMT)

NCT06803745
View directory record Official record
Conditions
Acute Leukemia, Acute Lymphoblastic Lymphoma
Interventions
200 cGy or 400 cGy total body irradiation (TBI)
Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Not listed
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 31, 2026, 9:56 PM EDT
Active, not recruiting Not applicable Interventional

A Collaborative Palliative and Leukemia Care Model for Patients With AML and MDS Receiving Non-Intensive Therapy

NCT03310918
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions
Palliative Care, Standard Leukemia care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 31, 2026, 9:56 PM EDT
Completed Phase 2 Interventional

Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT02518555
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Ibrutinib, Laboratory Biomarker Analysis, Pharmacological Study, Pneumococcal 13-valent Conjugate Vaccine, Quality-of-Life Assessment, Trivalent Influenza Vaccine
Biological · Drug · Other
Lead sponsor
Jennifer Woyach
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 31, 2026, 9:56 PM EDT
Recruiting Phase 2 Interventional

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

NCT05735717
View directory record Official record
Conditions
Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21, Cytogenetic Abnormality, CNS Leukemia, Minimal Residual Disease, Myelodysplasia, Juvenile Myelomonocytic Leukemia, Somatic Mutation, PTPN11 Gene Mutation, N-RAS Gene Amplification, Neurofibromatosis 1, NF1 Mutation, CBL Gene Mutation, Monosomy 7, Chromosome Abnormality, Fetal Hemoglobin, Lymphoblastic Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult
Interventions
Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam, Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells, Thymoglobulin, Cyclophosphamide
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 31, 2026, 9:56 PM EDT
Recruiting Phase 2 Interventional

BMT-06: Study of Intensity Modulated Total Marrow Irradiation (IM-TMI)

NCT04187105
View directory record Official record
Conditions
Acute Leukemia, MDS
Interventions
Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant, Conditioning regimen with half-matched (haploidentical) stem cell transplant
Radiation · Drug · Device + 1 more
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 31, 2026, 9:56 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL

NCT03467867
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
Venetoclax, Rituximab, Rituximab/Hyaluronidase Human
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 31, 2026, 9:56 PM EDT

About this Leukemia clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Leukemia as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results
Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Leukemia.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all condition pages, browse by drug or therapy, browse by U.S. city, browse by sponsor, or open the full search for Leukemia.